Extended Data Fig. 2: TMT-B completion time measurements across trial phases (all participants).

TMT-B completion time raw scores obtained from each participant across each phase of the study. Four time points are shown for all participants except for P2 who was withdrawn before initiating the titration phase. The two intermediate time points between presurgical baseline (first timepoint, Day 0 all participants) and treatment end measurements reflect many sources of inter-participant variation in times of measurements after surgery, surgical procedures (see Supplemental Methods, Surgical targeting and implantation) and hours of exposure to stimulation prior to “Treatment Start” TMT-B completion time measurement (see Supplemental Methods Titration Phase and Study design considerations). Exposure to stimulation is indicated by shaded gray regions and includes a brief exposure to stimulation at the time of surgery (green marker on gray bar). The range of separation for the 4 time points across participants varied: Baseline to Post-Surgery (range 55-91 days), Post-Surgery to Treatment Start (7-33 days) and Treatment Start to Treatment End (89-107 days). Abrupt changes with initial exposure to continuous DBS were evident in P3, P5, and P6.